Drug Profile
Research programme: purinergic P2 receptor antagonists - Merck
Alternative Names: AF-220; AF-221; AF-742; RO-4Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Roche
- Developer Merck & Co; Roche
- Class Diaminopyrimidines; Small molecules
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Overactive bladder; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-0 development in Pain in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Overactive bladder in Canada (PO)
- 11 Sep 2013 Phase-0 development is ongoing in USA